PT695360E - Adenovirus recombinantes deficientes, para a terapia genica de tumores - Google Patents

Adenovirus recombinantes deficientes, para a terapia genica de tumores

Info

Publication number
PT695360E
PT695360E PT94913649T PT94913649T PT695360E PT 695360 E PT695360 E PT 695360E PT 94913649 T PT94913649 T PT 94913649T PT 94913649 T PT94913649 T PT 94913649T PT 695360 E PT695360 E PT 695360E
Authority
PT
Portugal
Prior art keywords
disabilities
adenovirus
recombinant
tumor therapy
genetic tumor
Prior art date
Application number
PT94913649T
Other languages
English (en)
Inventor
Michel Perricaudet
Haddada Hedi
May Evelyne
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT695360E publication Critical patent/PT695360E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
PT94913649T 1993-04-22 1994-04-15 Adenovirus recombinantes deficientes, para a terapia genica de tumores PT695360E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9304745A FR2704234B1 (fr) 1993-04-22 1993-04-22 Virus recombinants, preparation et utilisation en therapie genique.

Publications (1)

Publication Number Publication Date
PT695360E true PT695360E (pt) 2006-09-29

Family

ID=9446321

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94913649T PT695360E (pt) 1993-04-22 1994-04-15 Adenovirus recombinantes deficientes, para a terapia genica de tumores

Country Status (15)

Country Link
EP (2) EP1652931A3 (pt)
JP (1) JPH08508879A (pt)
AT (1) ATE332386T1 (pt)
AU (1) AU696245B2 (pt)
DE (1) DE69434781T2 (pt)
DK (1) DK0695360T3 (pt)
ES (1) ES2264123T3 (pt)
FI (1) FI118011B (pt)
FR (1) FR2704234B1 (pt)
HU (1) HU220346B (pt)
NO (1) NO321454B1 (pt)
NZ (1) NZ265306A (pt)
PT (1) PT695360E (pt)
WO (1) WO1994024297A1 (pt)
ZA (1) ZA942778B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
ES2256842T4 (es) * 1993-10-25 2007-02-01 Canji, Inc. Vector de adenovirus recombinante y metodos de uso.
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2717495B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US6015665A (en) * 1995-02-13 2000-01-18 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
US7097972B1 (en) 1995-02-13 2006-08-29 Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US7807783B1 (en) 1995-04-03 2010-10-05 The Regents Of The University Of Michigan Methods and compositions for regulating FAS-associated apoptosis
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6482803B1 (en) 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
FR2790484B1 (fr) 1999-03-01 2003-01-03 Michel Marcel Andre Loiselet Petrins malaxeurs fermenteurs, dotes de dispositifs novateurs en la matiere, pour le petrissage des pates visco-elastiques et la production de levain pateux
FR2829136B1 (fr) 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
EP2331071A1 (en) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Novel multimodular assembly useful for intracellular delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells

Also Published As

Publication number Publication date
EP1652931A3 (fr) 2006-05-17
NO954132D0 (no) 1995-10-17
NO954132L (no) 1995-10-17
ES2264123T3 (es) 2006-12-16
JPH08508879A (ja) 1996-09-24
DK0695360T3 (da) 2006-11-13
EP0695360B1 (fr) 2006-07-05
DE69434781T2 (de) 2007-06-14
HUT73464A (en) 1996-08-28
WO1994024297A1 (fr) 1994-10-27
HU9503035D0 (en) 1995-12-28
DE69434781D1 (de) 2006-08-17
HU220346B (hu) 2001-12-28
FI954966A (fi) 1995-10-18
AU696245B2 (en) 1998-09-03
AU6572194A (en) 1994-11-08
FI954966A0 (fi) 1995-10-18
FR2704234A1 (fr) 1994-10-28
FI118011B (fi) 2007-05-31
NO321454B1 (no) 2006-05-15
ZA942778B (en) 1995-01-09
EP1652931A2 (fr) 2006-05-03
ATE332386T1 (de) 2006-07-15
NZ265306A (en) 1997-10-24
EP0695360A1 (fr) 1996-02-07
FR2704234B1 (fr) 1995-07-21

Similar Documents

Publication Publication Date Title
PT695360E (pt) Adenovirus recombinantes deficientes, para a terapia genica de tumores
FI871288A0 (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
BR9609270A (pt) Polinucleotídeo isolado e purificado peptídeo isolado e purificado processo para detectar a presença da câncer mamário em um paciente e kit para a detecção da presença de células neoplásticas mamárias em uma amostra
DK198883D0 (da) Fremgangsmade til fremstilling af menneskevaevs-plasminogenaktivator, dna-sekvens der koder for denne aktivator, replicerbar udtrykkelsesvektor for dna-sekvensen og microorganisme eller cellekultur transformeret med udtrykkelsesvektoren
DK0663010T3 (da) Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
ATE295739T1 (de) ADENOVIRALE VEKTOREN BEINHALTEND EIN PROSTATA SPEZIFISCHES ANTIGEN (PSA) ßRESPONSE ELEMENTß
DK0737207T3 (da) Inhibitorer for humant plasmin afledt af Kunitz-domæner
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
AR008847A1 (es) Construcciones de acidos nucleicos para la expresion regulada de un transgen en una celula hospedante para uso en la terapia fenica y lamanipulacion genetica, una celula aislada que los comprende y una composicion farmaceutica
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
FI962114A (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
ES2143475T3 (es) Genes de polifenol oxidasa.
IT8882551A0 (it) Per scarponi da sci. struttura di scafo, particolarmente
WO2000071078A3 (fr) Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
ES2178203T3 (es) Metodos y reactivos para modular la apoptosis.
WO2004003008A3 (en) Peptides for inducing apoptosis in tumor cells
DE59914061D1 (de) Das gen prv-1 und dessen verwendung
PT733370E (pt) Utilizacao da sequencia de um promotor genico para o tratamento de doencas reumaticas
SE9302856D0 (sv) Method and means for producing a plasmapeotein-binding protein
ES1022431Y (es) Plantilla aromtica para calzado perfeccionada.
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi